Advertisement: Simpsons Creative
Advertisement: EBCam mid banner
Advertisement: EY Mid banner
Advertisement: Cambridge Network
ARM Innovation Hub
Advertisement: Mogrify
Barr Ellison Solicitors – commercial property
Advertisement: RSM
RealVNC mid banner careers
RealVNC mid-banner general
Advertisement: TTP
Advertisement: Wild Knight Vodka
Mid banner advertisement: BDO
10 November, 2011 - 16:24 By News Desk

Use of EDG2 inhibitors for rheumatoid arthritis treatment

A Spanish university has developed a new EDG2 inhibitor compound for treatment of rheumatoid arthritis patients, specifically non-responder patients to conventional anti-inflammatory treatments. EDG2 blockage is useful to ameliorate clinical evolution of arthritis in presence of inflammatory activity. The university is looking for pharmaceutical companies interested in signing a license agreement.Ref: 11 ES 24D8 3N1L

Add new comment

Newsletter Subscription

Stay informed of the latest news and features